
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio is a promising biotech company with a positive outlook due to their strong pipeline of potential immunotherapy treatments, successful partnerships, and low expenses. However, there are potential risks such as legal disputes that could affect the stock price. Investors should closely monitor the results of the ongoing clinical trials for colon cancer and closely watch for any updates on ongoing legal matters.
Bears say
AnaptysBio is highly dependent on Jemperli, with a disconnect from investors who are not considering potential revenue inflection points. The company's royalty deal with Sagard Healthcare Royalty Partners has a cash inflow of $250 million, with an estimated remaining amount of $325 million to be paid off in the 2Q27 range. However, with only early data available, the potential for a non-operative approach may suggest limited demand for the company's product, and the lack of significant adverse events means there may not be enough data to support the potential of AnaptysBio's treatment.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares